Your monthly Kanjinti cost savings if eligible
The Kanjinti patient assistance program can provide your medication for free. We simply charge $49 per month for each medication to cover the cost of our services. With NiceRx, you will only pay $49 to obtain your Kanjinti, regardless of the retail price.
Am I eligible for the Kanjinti patient assistance program?
To find out if you are eligible for Kanjinti assistance you can apply online using our enrollment application. Each pharmaceutical company sets its eligibility criteria, and we will review your application individually to determine if you may be eligible. The three main factors to consider are:
- I am a permanent, legal resident of the United States or Puerto Rico
- I am uninsured or my insurance doesn’t cover my medication
- I meet certain income eligibility requirements
How do I apply for the Kanjinti patient assistance program?
Our application process aims to make it as easy as possible to apply for the Kanjinti patient assistance program. The first step is to complete our online enrollment application. We will ask you for details about your healthcare provider, your insurance plan, and your household income as this information is required by the pharmaceutical companies. We may be able to help you apply for other patient assistance programs too, so be sure to tell us about any medications you are taking as well as Kanjinti.
NiceRx will review your application and determine whether you may be eligible for Kanjinti assistance. If so, we will handle the full enrollment process for you and prepare all required documents for your healthcare provider to sign. Once you are successfully enrolled in the Kanjinti patient assistance program, we will help you manage your prescription refills by requesting refills on your behalf throughout your enrollment period. At the end of your enrollment period, we will contact you for updated information and seek to re-enroll you so you can continue to access affordable Kanjinti.
Is NiceRx a Kanjinti coupons provider?
NiceRx is a service provider that helps eligible individuals access the Kanjinti patient assistance program. We do not offer trial offers or free Kanjinti samples. When obtaining your medication through NiceRx, you will only pay $49 a month per medication. This will likely save you more money than if you were to use Kanjinti coupons, discount cards, or Kanjinti copay cards.
Can NiceRx help me get Kanjinti if I have insurance?
NiceRx may be able to help you if your insurance company will not pay for your Kanjinti medication. We may also be able to help if you have a high copay or coinsurance responsibility. Whether you have insurance or not, apply online using our enrollment application to find out more.
How much does Kanjinti cost without insurance?
Kanjinti prices without insurance will vary depending on how much you buy. Prices will also vary by retailer. As a guide, Kanjinti intravenous powder for injection anns 150 mg typically costs $1,400 for 1 powder for injection.
How much does Kanjinti cost with insurance?
The copay for Kanjinti will vary by the terms of your healthcare plan. To find out what you might need to pay for Kanjinti with insurance, your insurance provider or pharmacist will be able to help you calculate the copay costs with your current insurance.
What is Kanjinti?
Kanjinti is an FDA (U.S. Food and Drug Administration) approved medication manufactured by Amgen Inc. It is biosimilar to Herceptin (trastuzumab), meaning that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product and that there are no clinically meaningful differences between the biosimilar product and the reference product.
Trastuzumab targets HER2-expressing breast cancer cells in cancer patients and is indicated:
- For the adjuvant treatment of HER2 overexpressing node-positive or node-negative (ER/PR negative or with one high-risk feature) breast cancer, as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel, as part of a treatment regimen with docetaxel and carboplatin, or as a single agent following multi-modality anthracycline-based therapy
- For cancer treatment of adult patients with HER2 positive early breast cancer (EBC), in combination with paclitaxel for first-line treatment of HER2-overexpressing metastatic breast cancer, or as a single agent for the treatment of HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease
- In combination with cisplatin and capecitabine or 5-fluorouracil, for the treatment of patients with HER2 overexpressing metastatic gastric cancer or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease
Trastuzumab products can result in subclinical and clinical cardiac failure manifesting as CHF, and decreased LVEF, with the greatest risk when administered with anthracyclines.
Evaluation of cardiac function before and during treatment should be carried out. Discontinue Kanjinti for cardiomyopathy, infusion reactions, pulmonary toxicity, anaphylaxis, angioedema, interstitial pneumonitis, or acute respiratory distress syndrome.
What doses of Kanjinti are available?
Kanjinti is available in injection form, in the following doses: 420 mg lyophilized powder in a multiple-dose vial for reconstitution.
Your dose of Kanjinti will be based on your condition being treated as well as your body weight. Always speak with a healthcare professional about any changes to your dose so they can monitor and evaluate your condition.
Kanjinti active ingredients
Kanjinti contains trastuzumab-anns, a humanized IgG1 kappa monoclonal antibody, as the active ingredient. It selectively binds with high affinity to the extracellular domain of the human epidermal growth factor receptor 2 protein, HER2.
Kanjinti side effects
The most common side effects of Kanjinti in clinical trials include:
- Congestive heart failure
- Weight loss
- Upper respiratory tract infections
- Mucosal inflammation
In rare instances, Kanjinti can cause more serious side effects. These can include:
- Exacerbation of chemotherapy-induced neutropenia
- Left ventricular cardiac dysfunction, arrhythmias, hypertension, disabling cardiac failure, cardiomyopathy, and cardiac death
Your doctor will assess the benefits of using Kanjinti against your risk of side effects. Patients are encouraged to report negative side effects or adverse reactions of Kanjinti to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Kanjinti drug interactions
Kanjinti can interact with other medications. These include:
- Vaccines – BCG, rotavirus, rubella, smallpox, typhoid, yellow fever
- Antipsychotics – clozapine
- Immunosuppressants – fingolimod, ozanimod, siponimod
- DMARDs – leflunomide, teriflunomide
This list is not exhaustive and other prescription drugs may interact with Kanjinti.
You should not use Kanjinti if you:
- Are allergic to the active ingredient trastuzumab-anns
- Have had an allergic reaction to any of the other ingredients in Kanjinti
- Are pregnant or are planning to become pregnant – embryo-fetal toxicity, you are advised to use effective contraception
- Are breastfeeding or are planning to breastfeed – It may not be safe to breastfeed while using this medicine and for up to 7 months after your last dose
Talk to your doctor before using Kanjinti if you:
- Are taking any of the medications that could interact with Kanjinti
- Have heart disease, or congestive heart failure
- Have had a heart attack
- Have breathing problems
Kanjinti is the trademark brand name for trastuzumab-anns manufactured by Amgen Inc. A generic version of trastuzumab-anns is not available. Generic drugs are generally cheaper than brand-name drugs, but you can still find Kanjinti savings through NiceRx.
The content on this website is intended for information purposes only. It does not constitute medical advice. The information on this website should not be relied upon and is not a substitute for professional medical advice. You should always speak to your doctor regarding the risks and benefits of any treatment.